Sanofi Expands Its Neurology Research with Vigil Neuroscience Buyout

Paris, France - In a significant move to bolster its early-stage neurology pipeline, Sanofi SA has officially completed the acquisition of Vigil Neuroscience, Inc. The transaction, valued at around $470 million, secures all outstanding shares of Vigil at $8 per share in cash, with an additional deferred payment of $2 per share linked to the first commercial sale of the Alzheimer's disease treatment, VG-3927.

What This Means for Alzheimer's Research

The deal introduces VG-3927, an innovative oral TREM2 agonist aimed at combating Alzheimer's disease, into Sanofi's research and development portfolio. With plans to advance into phase 2 clinical trials, this acquisition marks a pivotal step in Sanofi's commitment to addressing neurodegenerative diseases. Notably, this agreement excludes Vigil's second clinical program, VGL101, from the transaction.

Financial Implications and Future Outlook

Sanofi has reassured stakeholders that this acquisition is aligned with its financial strategy, stating it will not impact the company's 2025 financial guidance. This strategic acquisition underscores Sanofi's dedication to pioneering treatments in the neurology sector, promising potential breakthroughs in Alzheimer's disease therapy.